Last Updated: 10 January 2025
RAAPID, a healthcare AI company at the forefront of innovation, has announced a key Series A funding round led by M12, Microsoft’s venture capital arm. While the total amount raised remains under wraps, this funding marks a critical step forward for RAAPID as it continues to reshape healthcare risk adjustment.
Alongside M12, other strategic investors have also backed RAAPID, reflecting broad confidence in the company’s Neuro-symbolic AI platform.
Though the valuation hasn’t been disclosed, RAAPID’s focus remains on delivering real-world impact over market speculation.
Healthcare systems often struggle with unstructured medical data, which accounts for over 70% of medical records outside of electronic health records (EHRs). This creates inefficiencies in care delivery and accurate reimbursements.
RAAPID’s Neuro-symbolic AI platform tackles this challenge by transforming disorganized data into actionable insights, enabling healthcare providers to improve risk capture and close care gaps.
"Our vision extends beyond traditional risk adjustment. We're creating a future where AI augments healthcare professionals' capabilities, leading to better patient outcomes and more accurate appropriate reimbursements. This investment from M12 accelerates our mission to transform healthcare through advanced AI."
Chetan Parikh, Founder and CEO of RAAPID
RAAPID has achieved 300% revenue growth in 2024, underscoring its effectiveness as a partner to leading U.S. health systems. Its VisionAI technology has been pivotal in helping organizations achieve faster chart reviews, more accurate coding, and improved reimbursements.
The Series A funding will enable RAAPID to scale its Neuro-symbolic AI platform, enhancing its ability to meet the needs of healthcare payers and providers. The company plans to expand its product offerings, ensuring even broader adoption of its cutting-edge technology.
Key areas of investment include hiring top talent, accelerating research and development, and growing its presence in new markets. With these initiatives, RAAPID aims to further improve healthcare outcomes and operational efficiency across the industry.
RAAPID was founded by Chetan Parikh, a visionary leader with a mission to revolutionize healthcare technology.
With over 25 years of experience, RAAPID’s leadership team has collaborated with experts from the world’s leading tech companies to create reliable and innovative solutions.
The company’s HITRUST-certified Neuro-symbolic AI platform sets it apart. By combining neural networks with a comprehensive medical knowledge graph—housing over 4 million clinical entities and 50 million relationships—RAAPID delivers unparalleled accuracy in risk adjustment and care gap identification.
M12’s investment reflects Microsoft’s commitment to advancing transformative healthcare technologies. As Microsoft’s venture capital arm, M12 provides its portfolio companies with unparalleled access to resources and expertise.
"Healthcare organizations are increasingly seeking innovative solutions to manage risk and improve care delivery in value-based arrangements. RAAPID’s AI-driven risk adjustment platform aligns perfectly with our investment strategy.”
Todd Graham, Managing Partner at M12
With this Series A funding, the company is well-positioned to continue leading the charge in risk adjustment and population health management, making healthcare more efficient and impactful for all stakeholders.
